Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Novel approach for CES1 genotyping: integrating single nucleotide variants and structural variation

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics

    Research output: Contribution to journalReviewResearchpeer-review

  4. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19

    Research output: Contribution to journalReviewResearchpeer-review

  2. Pulmonary administration of remdesivir in the treatment of COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: Development of a specific procedure for genotyping of CES1A1 (CES1) and CES1A2, a hybrid of CES1A1 and the pseudogene CES1P1.

MATERIALS & METHODS: The number of CES1A1 and CES1A2 copies and that of CES1P1 were determined using real-time PCR. Long range PCRs followed by secondary PCRs allowed sequencing of single nucleotide variants in CES1A1 and CES1A2. Results & conlusion: A procedure consisting of two main steps was developed. Its first main step, the copy number determination, informed about presence of CES1A2 . This information enabled choice of PCR in the second main step, which selectively amplified CES1A1 and, if present, also CES1A2, for subsequent sequencing. Examination of 501 DNA samples suggested that our procedure is specific with potential for personalization of drug treatments.

Original languageEnglish
JournalPharmacogenomics
ISSN1462-2416
DOIs
Publication statusE-pub ahead of print - 19 Feb 2018

    Research areas

  • Journal Article

ID: 52796485